To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using [18F]AZD4694.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Male or female, of any race or/ethnicity

• ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician

Exclusion Criteria:

• Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse

• Participated in a PET study within the last 12 months

• Pregnancy or lactation